Featured Research

from universities, journals, and other organizations

In first moments of infection, a division and a decision

Date:
March 2, 2014
Source:
University of California, San Diego Health Sciences
Summary:
Using technologies and computational modeling that trace the destiny of single cells, researchers describe for the first time the earliest stages of fate determination among white blood cells called T lymphocytes, providing new insights that may help drug developers create more effective, longer-lasting vaccines against microbial pathogens or cancer.

This is the T lymphocyte.
Credit: National Institute of Allergy and Infectious Diseases

Using technologies and computational modeling that trace the destiny of single cells, researchers at the University of California, San Diego School of Medicine describe for the first time the earliest stages of fate determination among white blood cells called T lymphocytes, providing new insights that may help drug developers create more effective, longer-lasting vaccines against microbial pathogens or cancer.

The findings are published in the March 2, 2014 online issue of Nature Immunology.

Naοve T lymphocytes patrol the front lines of the human body’s defense against infection, circulating in blood and tissues, searching for invasive microbes and other foreign antigens. They’re called “naοve” because they have not yet encountered an invader. When they do, these T cells activate and divide, giving rise to two types of daughter cells: “effector lymphocytes” responsible for immediate host defense and “memory lymphocytes” that provide long-term protection from similar infections.

“Researchers have been trying for a very long time to understand when and how T lymphocytes give rise to effector and memory cells during an infection,” said John T. Chang, MD, assistant professor in the Department of Medicine and the study’s co-principal investigator, along with Gene W. Yeo, PhD, assistant professor in the Department of Cellular and Molecular Medicine and Institute for Genomic Medicine.

However, all studies up to this point were based on analyses on bulk populations of cells, making it impossible to understand fate decisions made by individual cells. First authors Janilyn Arsenio, a postdoctoral fellow in the Chang lab and Boyko Kakaradov, a graduate student in the Yeo lab and UCSD Bioinformatics graduate program said that they took advantage of recent technological advances in single-cell gene expression profiling and cutting-edge machine-learning algorithms to address this question on a level of detail that was not previously possible.

Chang, Yeo and colleagues discovered that the decision by an individual T cell to produce effector and memory cells is made almost at the moment of infection. “The ‘mother’ lymphocyte seems to divide into two daughter cells that are already different from birth,” said Chang, “with one becoming an effector cell while its sister becomes a memory cell.”

Chang noted that the primary purpose of vaccines is to produce strong and durable immune protection, which depends heavily upon generation of memory lymphocytes. “Our work suggests that the way T lymphocytes divide early during a microbial infection might be critical to whether or not they give rise to long-lived memory cells. Strategies that improve this process could potentially enhance durable immunity and help us to design more effective vaccines.”


Story Source:

The above story is based on materials provided by University of California, San Diego Health Sciences. Note: Materials may be edited for content and length.


Journal Reference:

  1. Janilyn Arsenio, Boyko Kakaradov, Patrick J Metz, Stephanie H Kim, Gene W Yeo, John T Chang. Early specification of CD8 T lymphocyte fates during adaptive immunity revealed by single-cell gene-expression analyses. Nature Immunology, 2014; DOI: 10.1038/ni.2842

Cite This Page:

University of California, San Diego Health Sciences. "In first moments of infection, a division and a decision." ScienceDaily. ScienceDaily, 2 March 2014. <www.sciencedaily.com/releases/2014/03/140302143513.htm>.
University of California, San Diego Health Sciences. (2014, March 2). In first moments of infection, a division and a decision. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/03/140302143513.htm
University of California, San Diego Health Sciences. "In first moments of infection, a division and a decision." ScienceDaily. www.sciencedaily.com/releases/2014/03/140302143513.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins